Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Roger Waltzman

JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis

New England Journal of Medicine

English

Related publications

Cost-Effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

Journal of Health Economics and Outcomes Research

English

Primary Myelofibrosis Associated Glomerulopathy: Significant Improvement After Therapy With Ruxolitinib

English

Efficacy of Ruxolitinib for Myelofibrosis

Expert Opinion on Pharmacotherapy

English

Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects

Clinical Lymphoma, Myeloma and Leukemia

Cancer Research

English

Ruxolitinib as an Emerging Treatment in Myelofibrosis

Blood and Lymphatic Cancer: Targets and Therapy

English

Placebo Versus Best-Available-Therapy Control Group in Clinical Trials for Pharmacologic Therapies: Which Is Better?

Proceedings of the American Thoracic Society

English

Sweet Syndrome Successfully Treated With Ruxolitinib in JAK-2 Positive Myeloproliferative Disorder

English

Safety and Efficacy of Ruxolitinib in Myelofibrosis Patients Without Splenomegaly

British Journal of Haematology

English

Definition and Management of Ruxolitinib Treatment Failure in Myelofibrosis

Blood Cancer Journal

English